Kiran Mazumdar Shaw founded Biocon in 1978 in Bangalore as India's first biotech company. Starting with just two employees and operating out of a rented house garage with an initial capital of Rs. 10,000, Biocon focused initially on producing enzymes for use in industries like brewing. In the 1990s, Shaw pivoted Biocon's focus to biopharmaceuticals as its main business. Under her leadership, Biocon has grown to become a major biopharmaceutical company in India with facilities for producing insulin and statins. It has also expanded into areas like research services. Shaw's entrepreneurship and leadership has been instrumental in the growth of India's biotech sector.
Kiran Mazumdar Shaw is an Indian entrepreneur who founded Biocon, India's largest biotechnology company. After completing her education in zoology, she moved to Ireland and joined Biocon Biochemicals Limited as a trainee manager in 1978. In 1979, she founded Biocon India in collaboration with Biocon Biochemicals. Starting from her garage with only a few rupees, Biocon grew to become a major biopharmaceutical company under Kiran's leadership, pioneering the development of biosimilars and enzymes in India. Biocon now offers a range of biopharmaceuticals, enzymes, and clinical research services. Kiran is recognized for transforming Biocon into a globally recognized biotech company through her
Kiran Mazumdar Shaw founded Biocon Limited in 1978 in Bangalore, India, becoming India's first biotechnology company. She faced challenges securing funding as a woman but grew the company from producing enzymes to a fully integrated biopharmaceutical company. She has received numerous awards including EY World Entrepreneur of the Year in 2020. She overcame obstacles through her unique ideas and vision to transform healthcare in India.
Kiran Mazumdar Shaw is the chairperson and managing director of Biocon, India's largest biotechnology company. She founded Biocon in 1978 after completing her education in Australia. Under her stewardship, Biocon has transformed from an industrial enzymes company to an integrated biopharmaceutical company recognized as a pioneering biotech enterprise in India. She continues to receive recognition for her accomplishments, being listed among the most powerful women in the world by Forbes.
Kiran Mazumdar-Shaw is an Indian entrepreneur who is the founder and chairperson of Biocon Limited, a biotechnology company based in Bangalore, India. She studied fermentation science and became the first woman to earn a degree in brewing. When she was unable to find work in her field in India due to gender discrimination, she started her own company Biocon in 1978 with just $500. Under her leadership, Biocon has grown into a major biotechnology company with over $800 million in annual revenue and has helped advance India's biotechnology industry. She has also established healthcare and education programs through the Biocon Foundation to benefit the underprivileged in India.
Biocon is an integrated biopharmaceutical company based in India with four business divisions: small molecules and enzymes, branded formulations, research services, and novel molecules. The document discusses Biocon's business overview, growth opportunities in key therapeutic areas like diabetes and oncology, strong partnerships with large pharmaceutical companies, and promising pipeline of novel drug candidates. Biocon has a diversified business model and revenues, and is well-positioned to benefit from the large and growing biopharma industry globally.
Successful entrepreneur (kiran muzumdar shaw) by saisai guntapelliwar
successful entrepreneurs- kiran muzumdar shaw . It is a ppt on the successful leader and the richest women in India and the worlds 7th largest pharmaceutical company chairman kiran muzumdar shaw .The story behind her success and journy how she face the problem and overcome from that situation.
Kiran Mazumdar-Shaw is the chairman and managing director of Biocon Limited, India's largest biotechnology company. She received a B.Sc. in Zoology and later qualified as a master brewer. In 1978, she founded Biocon India with an initial capital of Rs. 10,000 and grew it to become a pioneering biotech enterprise in India. She has received many prestigious awards for her achievements as an entrepreneur and being a role model for women in business.
Dr. Kiran Mazumdar Shaw founded Biocon in 1978 with Rs. 10,000 in capital. She has received many prestigious awards for her achievements. Biocon is now India's largest biopharmaceutical company and Dr. Shaw is one of India's richest women. Biocon uses a split business technique to divide its business into subsidiaries that collaborate on pre-clinical discovery, clinical development, and commercialization of health products. This structure drives innovation and provides multiple revenue streams. Biocon employs over 3,600 people and has strategic collaborations with global companies. Its objective is to become a globally distinguished integrated biotechnology enterprise.
Kiran Mazumdar Shaw is an Indian entrepreneur who founded Biocon, India's largest biotechnology company. After completing her education in zoology, she moved to Ireland and joined Biocon Biochemicals Limited as a trainee manager in 1978. In 1979, she founded Biocon India in collaboration with Biocon Biochemicals. Starting from her garage with only a few rupees, Biocon grew to become a major biopharmaceutical company under Kiran's leadership, pioneering the development of biosimilars and enzymes in India. Biocon now offers a range of biopharmaceuticals, enzymes, and clinical research services. Kiran is recognized for transforming Biocon into a globally recognized biotech company through her
Kiran Mazumdar Shaw founded Biocon Limited in 1978 in Bangalore, India, becoming India's first biotechnology company. She faced challenges securing funding as a woman but grew the company from producing enzymes to a fully integrated biopharmaceutical company. She has received numerous awards including EY World Entrepreneur of the Year in 2020. She overcame obstacles through her unique ideas and vision to transform healthcare in India.
Kiran Mazumdar Shaw is the chairperson and managing director of Biocon, India's largest biotechnology company. She founded Biocon in 1978 after completing her education in Australia. Under her stewardship, Biocon has transformed from an industrial enzymes company to an integrated biopharmaceutical company recognized as a pioneering biotech enterprise in India. She continues to receive recognition for her accomplishments, being listed among the most powerful women in the world by Forbes.
Kiran Mazumdar-Shaw is an Indian entrepreneur who is the founder and chairperson of Biocon Limited, a biotechnology company based in Bangalore, India. She studied fermentation science and became the first woman to earn a degree in brewing. When she was unable to find work in her field in India due to gender discrimination, she started her own company Biocon in 1978 with just $500. Under her leadership, Biocon has grown into a major biotechnology company with over $800 million in annual revenue and has helped advance India's biotechnology industry. She has also established healthcare and education programs through the Biocon Foundation to benefit the underprivileged in India.
Biocon is an integrated biopharmaceutical company based in India with four business divisions: small molecules and enzymes, branded formulations, research services, and novel molecules. The document discusses Biocon's business overview, growth opportunities in key therapeutic areas like diabetes and oncology, strong partnerships with large pharmaceutical companies, and promising pipeline of novel drug candidates. Biocon has a diversified business model and revenues, and is well-positioned to benefit from the large and growing biopharma industry globally.
Successful entrepreneur (kiran muzumdar shaw) by saisai guntapelliwar
successful entrepreneurs- kiran muzumdar shaw . It is a ppt on the successful leader and the richest women in India and the worlds 7th largest pharmaceutical company chairman kiran muzumdar shaw .The story behind her success and journy how she face the problem and overcome from that situation.
Kiran Mazumdar-Shaw is the chairman and managing director of Biocon Limited, India's largest biotechnology company. She received a B.Sc. in Zoology and later qualified as a master brewer. In 1978, she founded Biocon India with an initial capital of Rs. 10,000 and grew it to become a pioneering biotech enterprise in India. She has received many prestigious awards for her achievements as an entrepreneur and being a role model for women in business.
Dr. Kiran Mazumdar Shaw founded Biocon in 1978 with Rs. 10,000 in capital. She has received many prestigious awards for her achievements. Biocon is now India's largest biopharmaceutical company and Dr. Shaw is one of India's richest women. Biocon uses a split business technique to divide its business into subsidiaries that collaborate on pre-clinical discovery, clinical development, and commercialization of health products. This structure drives innovation and provides multiple revenue streams. Biocon employs over 3,600 people and has strategic collaborations with global companies. Its objective is to become a globally distinguished integrated biotechnology enterprise.
Kiran Mazumdar-Shaw is an Indian entrepreneur who is the founder and chairperson of Biocon, India's largest biotechnology company. She founded Biocon in 1978 with just Rs. 10,000 in capital. Under her leadership, Biocon has grown into a major biotechnology firm with commercial success in enzymes, biopharmaceuticals, and research. She faced challenges as one of the first female entrepreneurs in India in the biotechnology field but overcame obstacles to build Biocon into a multi-billion dollar company.
A competitive market strategy for Himalaya Drugs to launch a new ayurvedic beauty product in the market and build an competitive advance over its competitors
The biocon pharmaceutical ppt is majorly focused on the background, the history and revenue, EBITDA, number of employees working, the segment, turnover of the company of FY16 and SWOT analysis.
Rahul Bajaj is an Indian businessman and chairman of Bajaj Group. He took over as chairman of Bajaj Auto in 1965 at a young age of 26. Under his leadership, Bajaj Auto grew to become the top scooter manufacturer in India in the 1980s. He established new factories, launched new models like the popular Bajaj Chetak scooter, and navigated challenges to rebuild the company's success. Rahul Bajaj is credited with creating one of India's most successful companies and is respected for his business and entrepreneurial expertise.
Kiran Mazumdar was honored as the 92nd most powerful woman in the world. She started her career as a brewer in Australia but founded Biocon Biochemicals in India in 1978 out of a rented garage with an initial investment of $150. Through hard work and perseverance, Biocon grew into a large biotechnology company, becoming the first Indian biotech company to receive US funding and crossing $1 billion in market capitalization on its first day of going public.
Dabur India Limited is India's leading FMCG company with a turnover of Rs. 5,283 crore. It produces ayurvedic medicines and consumer products that are marketed in over 50 countries. Some of Dabur's top selling brands include Dabur Chyawanprash, Dabur Hajmola, Dabur Amla hair oil, and Dabur Red toothpaste. Dabur has manufacturing plants in India and several other countries, and continues to expand its operations both domestically and globally through new product launches, acquisitions, and facility investments.
I, Chirag Beladiya a student of PGDM of ST KABIR INSTITUTE OF PROFESSIONAL STUDIES (SKIPS) hereby declare that the Project entitled “ Understanding of dairy products,HORECA Sales and Distribution Management.
My first word of gratitude is due to Mr. RAZAK MANSURI– Sales Manager, PARAG FOODS PVT LTD, Ahmedabad, my corporate guide, for his kind help and support and his valuable guidance throughout my project. I am thankful to him.
The document analyzes the garment industry in Bangladesh using the PESTEL framework. It discusses the positive impact of the industry on the country's economy and development despite political and safety challenges. The government has implemented reforms to address issues like strengthening labor laws and improving factory safety to develop a more sustainable industry.
This document provides information about CavinKare's rural marketing project for their Chik Shampoo sachets. It discusses CavinKare's company profile, products, competitors, marketing strategies, and how Chik Shampoo was developed to target rural audiences through affordable sachet packaging and effective communication strategies emphasizing the benefits of shampoo over soap for hair care. Key highlights include CavinKare achieving a 19% market share in shampoos through Chik and Nyle, and their pioneering of sachet packaging which expanded access to shampoos in rural India.
Godrej Cinthol soap is a skin care product made by Godrej Industries. The FMCG market in India is growing rapidly due to rising incomes and favorable demographics. Cinthol soap was launched in 1952 and was initially positioned as a toilet soap, but Godrej is now trying to make it more relevant to young male consumers. Cinthol faces competition from other personal care brands that have larger market shares. While Cinthol was once very popular, its market share has declined over time. Godrej needs to better position Cinthol and understand customer needs to increase its market share in the growing FMCG sector.
The document provides details about Tanishq, a jewellery brand owned by Titan. It discusses Tanishq's evolution, growth, products, competitors like Carbon and Gili, marketing strategies using the 4Ps, segmentation, SWOT analysis, and recommendations to make it a global brand. Tanishq is India's largest jewellery brand known for quality, design, and services. It aims to increase domestic market penetration and expand abroad using shop-in-shop concepts. The document recommends how Tanishq can become a leading global jewellery brand.
Study of consumer oriented sales promotion in FMCG sector tushar choleTushar Cholepatil
This document provides details about a study conducted on consumer-oriented sales promotion in the fast-moving consumer goods (FMCG) sector. It includes an introduction to the concept of sales promotion and consumer-oriented sales promotion tools. It also discusses factors influencing consumer-oriented sales promotion strategies such as target market, product nature, product life cycle stage, and available promotion budget. The study aims to understand consumer perceptions of various sales promotion techniques used by FMCG companies.
This document provides an overview of a research report on Lakme, a cosmetics brand owned by Hindustan Unilever Ltd. The report includes an introduction to the company's history and objectives. It outlines the research methodology used, which involved primary data collection through questionnaires and secondary data collection from sources like company reports, magazines and articles. It discusses Lakme's competitive environment and profiles elements of the company like its board of directors, research and development team and human resources. The report also includes chapters on data analysis, a SWOT analysis of Lakme, conclusions and limitations. It aims to understand how Lakme can improve its brand personality and promotional strategies to maintain its leading market position.
This document discusses sales promotion strategies for Parachute coconut hair oil in India. It summarizes Marico's market position and brands in hair oils. For consumer promotions, it proposes a loyalty program with reward points for free gifts, student discounts, and rural awareness camps. For trade promotions, it suggests best product displays, incentives for retailers, and contests. For business promotions, it recommends awards for top sales employees and distributors. It also outlines Parachute's existing communication strategy around nourishment and proposes emphasizing purity and innovative packaging.
Dabur India Case Study 2014 By Subin KannanSubin Snk
Mba Degree University
Dabur india
Case study
Alternatives
Suggestion
Conclusion
Managerial Economics
Business Environment
indian University
Calicut university
Research
First Prize
School Of Management Studies
Rural marketing strategies of dabur amla hair oilpratheeksharaoa
Dabur India Ltd is one of India's largest FMCG companies known for its Ayurvedic and natural healthcare products. It markets brands like Dabur, Vatika, Anmol, and Hajmola. Rural markets account for 55% of sales of Dabur Amla hair oil, its largest hair care product. To target these rural customers, Dabur uses promotional strategies like TV, radio, and newspaper ads as well as on-ground events. It conducts beauty contests and empowers women through hair education. Dabur has expanded its retail reach to 25 lakh outlets to better serve rural consumers across India.
The company has a long history of acquisitions.
Coca-Cola acquired Minute Maid in 1960,the Indian cola brand
Coca-Cola was the leading soft drink brand in India until 1977 when it left rather than reveal its formula to the government and reduce its equity stake as required under the Foreign Exchange Regulation Act (FERA) which governed the operations of foreign companies in India
Coca-Cola returned to India in 1993, cementing its presence with a deal that gave Coca-Cola ownership of the nation's top soft-drink brands and bottling network.
Coke acquired local popular Indian brands including Thumbs Up, Limca, Maaza, Citra and Gold Spot provided not only physical manufacturing, bottling, and distribution assets but also strong consumer preference
This document provides an overview of a research project conducted on the consumer behavior and perception of women towards Lakme cosmetic products. It includes an acknowledgement section thanking those who supported and guided the research. It also includes a certificate verifying the completion of the project. The document consists of 16 chapters that cover topics such as an introduction to consumer behavior and perception, a literature review on the cosmetic industry and Lakme, the research methodology used which involved surveys, an analysis and interpretation of the survey results, findings of the research, suggestions based on the findings, and a conclusion. The overall purpose of the research was to understand the consumer behavior and perception of women regarding awareness and purchase of Lakme cosmetic products.
Kiran Majumdar Shaw is an Indian entrepreneur who founded Biocon, a biotechnology company based in Bangalore, in 1978. She overcame challenges related to her youth, gender and the lack of infrastructure in India to build Biocon into a fully integrated biopharmaceutical company. Under her leadership, Biocon became the first Indian company to export enzymes internationally and the first to receive US funding. Today, Biocon conducts research in areas like diabetes and oncology. Shaw has received numerous awards for her pioneering work, including India's Padma Bhushan, and has been named one of the most influential people in the world by TIME magazine.
This document provides an overview and summary of a white paper titled "Power Women in FinTech Index: Bridging the Gender Gap". It discusses the lack of gender diversity in the financial technology (FinTech) sector based on research and interviews. Key points made include:
- Women are underrepresented in leadership roles in both financial institutions and technology companies. Improving gender diversity is important for developing inclusive products and solutions.
- The white paper aims to document the current state of gender diversity in FinTech, provide recommendations to improve it, and recognize women who have achieved leadership positions.
- Statistics presented show the disproportionately low representation of women in senior roles in banking, technology companies, and engineering fields. The business
Kiran Mazumdar-Shaw is an Indian entrepreneur who is the founder and chairperson of Biocon, India's largest biotechnology company. She founded Biocon in 1978 with just Rs. 10,000 in capital. Under her leadership, Biocon has grown into a major biotechnology firm with commercial success in enzymes, biopharmaceuticals, and research. She faced challenges as one of the first female entrepreneurs in India in the biotechnology field but overcame obstacles to build Biocon into a multi-billion dollar company.
A competitive market strategy for Himalaya Drugs to launch a new ayurvedic beauty product in the market and build an competitive advance over its competitors
The biocon pharmaceutical ppt is majorly focused on the background, the history and revenue, EBITDA, number of employees working, the segment, turnover of the company of FY16 and SWOT analysis.
Rahul Bajaj is an Indian businessman and chairman of Bajaj Group. He took over as chairman of Bajaj Auto in 1965 at a young age of 26. Under his leadership, Bajaj Auto grew to become the top scooter manufacturer in India in the 1980s. He established new factories, launched new models like the popular Bajaj Chetak scooter, and navigated challenges to rebuild the company's success. Rahul Bajaj is credited with creating one of India's most successful companies and is respected for his business and entrepreneurial expertise.
Kiran Mazumdar was honored as the 92nd most powerful woman in the world. She started her career as a brewer in Australia but founded Biocon Biochemicals in India in 1978 out of a rented garage with an initial investment of $150. Through hard work and perseverance, Biocon grew into a large biotechnology company, becoming the first Indian biotech company to receive US funding and crossing $1 billion in market capitalization on its first day of going public.
Dabur India Limited is India's leading FMCG company with a turnover of Rs. 5,283 crore. It produces ayurvedic medicines and consumer products that are marketed in over 50 countries. Some of Dabur's top selling brands include Dabur Chyawanprash, Dabur Hajmola, Dabur Amla hair oil, and Dabur Red toothpaste. Dabur has manufacturing plants in India and several other countries, and continues to expand its operations both domestically and globally through new product launches, acquisitions, and facility investments.
I, Chirag Beladiya a student of PGDM of ST KABIR INSTITUTE OF PROFESSIONAL STUDIES (SKIPS) hereby declare that the Project entitled “ Understanding of dairy products,HORECA Sales and Distribution Management.
My first word of gratitude is due to Mr. RAZAK MANSURI– Sales Manager, PARAG FOODS PVT LTD, Ahmedabad, my corporate guide, for his kind help and support and his valuable guidance throughout my project. I am thankful to him.
The document analyzes the garment industry in Bangladesh using the PESTEL framework. It discusses the positive impact of the industry on the country's economy and development despite political and safety challenges. The government has implemented reforms to address issues like strengthening labor laws and improving factory safety to develop a more sustainable industry.
This document provides information about CavinKare's rural marketing project for their Chik Shampoo sachets. It discusses CavinKare's company profile, products, competitors, marketing strategies, and how Chik Shampoo was developed to target rural audiences through affordable sachet packaging and effective communication strategies emphasizing the benefits of shampoo over soap for hair care. Key highlights include CavinKare achieving a 19% market share in shampoos through Chik and Nyle, and their pioneering of sachet packaging which expanded access to shampoos in rural India.
Godrej Cinthol soap is a skin care product made by Godrej Industries. The FMCG market in India is growing rapidly due to rising incomes and favorable demographics. Cinthol soap was launched in 1952 and was initially positioned as a toilet soap, but Godrej is now trying to make it more relevant to young male consumers. Cinthol faces competition from other personal care brands that have larger market shares. While Cinthol was once very popular, its market share has declined over time. Godrej needs to better position Cinthol and understand customer needs to increase its market share in the growing FMCG sector.
The document provides details about Tanishq, a jewellery brand owned by Titan. It discusses Tanishq's evolution, growth, products, competitors like Carbon and Gili, marketing strategies using the 4Ps, segmentation, SWOT analysis, and recommendations to make it a global brand. Tanishq is India's largest jewellery brand known for quality, design, and services. It aims to increase domestic market penetration and expand abroad using shop-in-shop concepts. The document recommends how Tanishq can become a leading global jewellery brand.
Study of consumer oriented sales promotion in FMCG sector tushar choleTushar Cholepatil
This document provides details about a study conducted on consumer-oriented sales promotion in the fast-moving consumer goods (FMCG) sector. It includes an introduction to the concept of sales promotion and consumer-oriented sales promotion tools. It also discusses factors influencing consumer-oriented sales promotion strategies such as target market, product nature, product life cycle stage, and available promotion budget. The study aims to understand consumer perceptions of various sales promotion techniques used by FMCG companies.
This document provides an overview of a research report on Lakme, a cosmetics brand owned by Hindustan Unilever Ltd. The report includes an introduction to the company's history and objectives. It outlines the research methodology used, which involved primary data collection through questionnaires and secondary data collection from sources like company reports, magazines and articles. It discusses Lakme's competitive environment and profiles elements of the company like its board of directors, research and development team and human resources. The report also includes chapters on data analysis, a SWOT analysis of Lakme, conclusions and limitations. It aims to understand how Lakme can improve its brand personality and promotional strategies to maintain its leading market position.
This document discusses sales promotion strategies for Parachute coconut hair oil in India. It summarizes Marico's market position and brands in hair oils. For consumer promotions, it proposes a loyalty program with reward points for free gifts, student discounts, and rural awareness camps. For trade promotions, it suggests best product displays, incentives for retailers, and contests. For business promotions, it recommends awards for top sales employees and distributors. It also outlines Parachute's existing communication strategy around nourishment and proposes emphasizing purity and innovative packaging.
Dabur India Case Study 2014 By Subin KannanSubin Snk
Mba Degree University
Dabur india
Case study
Alternatives
Suggestion
Conclusion
Managerial Economics
Business Environment
indian University
Calicut university
Research
First Prize
School Of Management Studies
Rural marketing strategies of dabur amla hair oilpratheeksharaoa
Dabur India Ltd is one of India's largest FMCG companies known for its Ayurvedic and natural healthcare products. It markets brands like Dabur, Vatika, Anmol, and Hajmola. Rural markets account for 55% of sales of Dabur Amla hair oil, its largest hair care product. To target these rural customers, Dabur uses promotional strategies like TV, radio, and newspaper ads as well as on-ground events. It conducts beauty contests and empowers women through hair education. Dabur has expanded its retail reach to 25 lakh outlets to better serve rural consumers across India.
The company has a long history of acquisitions.
Coca-Cola acquired Minute Maid in 1960,the Indian cola brand
Coca-Cola was the leading soft drink brand in India until 1977 when it left rather than reveal its formula to the government and reduce its equity stake as required under the Foreign Exchange Regulation Act (FERA) which governed the operations of foreign companies in India
Coca-Cola returned to India in 1993, cementing its presence with a deal that gave Coca-Cola ownership of the nation's top soft-drink brands and bottling network.
Coke acquired local popular Indian brands including Thumbs Up, Limca, Maaza, Citra and Gold Spot provided not only physical manufacturing, bottling, and distribution assets but also strong consumer preference
This document provides an overview of a research project conducted on the consumer behavior and perception of women towards Lakme cosmetic products. It includes an acknowledgement section thanking those who supported and guided the research. It also includes a certificate verifying the completion of the project. The document consists of 16 chapters that cover topics such as an introduction to consumer behavior and perception, a literature review on the cosmetic industry and Lakme, the research methodology used which involved surveys, an analysis and interpretation of the survey results, findings of the research, suggestions based on the findings, and a conclusion. The overall purpose of the research was to understand the consumer behavior and perception of women regarding awareness and purchase of Lakme cosmetic products.
Kiran Majumdar Shaw is an Indian entrepreneur who founded Biocon, a biotechnology company based in Bangalore, in 1978. She overcame challenges related to her youth, gender and the lack of infrastructure in India to build Biocon into a fully integrated biopharmaceutical company. Under her leadership, Biocon became the first Indian company to export enzymes internationally and the first to receive US funding. Today, Biocon conducts research in areas like diabetes and oncology. Shaw has received numerous awards for her pioneering work, including India's Padma Bhushan, and has been named one of the most influential people in the world by TIME magazine.
This document provides an overview and summary of a white paper titled "Power Women in FinTech Index: Bridging the Gender Gap". It discusses the lack of gender diversity in the financial technology (FinTech) sector based on research and interviews. Key points made include:
- Women are underrepresented in leadership roles in both financial institutions and technology companies. Improving gender diversity is important for developing inclusive products and solutions.
- The white paper aims to document the current state of gender diversity in FinTech, provide recommendations to improve it, and recognize women who have achieved leadership positions.
- Statistics presented show the disproportionately low representation of women in senior roles in banking, technology companies, and engineering fields. The business
Kiran Mazumdar Shaw is an Indian entrepreneur and biotechnologist. She is the founder and executive chairperson of Biocon, India's largest biotechnology company. Some key points:
- She was born in 1953 in Bangalore and received a B.Sc in Zoology from Bangalore University and a master's in brewing from Ballarat University in Australia.
- In 1978, she started Biocon in her garage in Bangalore with Rs. 10,000 in capital. Biocon became the first Indian company to export enzymes to the US and Europe.
- Under her leadership, Biocon has grown into one of the top biotechnology companies in the world. It conducts research in
The document provides biographical information about Sundar Pichai, the CEO of Google. It details that he was born in 1972 in India and educated at IIT Kharagpur and Stanford University. It outlines his career at Google, starting in 2004 and rising to become Senior Vice President. It notes his role in leading major Google products like Chrome OS, Android, and Gmail. The document praises Pichai's leadership skills and mentions that he is well-liked at Google for being collaborative, hard-working, and humble.
State Bank of India (SBI) is the largest commercial bank in India, with over 200 years of history. SBI has a vast network across India and numerous subsidiaries, offering an array of banking and financial services. As the largest bank in India, SBI plays an important role as a agent of the Reserve Bank of India and in providing critical services to both retail and commercial customers.
Leadership Style of the richest Indian Mukesh ambaniTirtha Mal
Mukesh Ambani is the richest man in India and chairman of Reliance Industries, the largest company in India by market value. He dropped out of Stanford University with an MBA to help his father build Reliance into a major conglomerate. Ambani's leadership style emphasizes empowering employees, thinking innovatively, and having a vision for expansion. He has received numerous business awards and leads Reliance in pursuing major projects in oil, gas, and petrochemicals to become a global industrial powerhouse.
Chanda kochhar-A successful business tycoonManvi Sehgal
Chanda Kochhar is the Managing Director and CEO of ICICI Bank, India's largest private bank. She has transformed ICICI Bank from a corporate bank to a retail bank to a universal bank. After obtaining her master's degree, she joined ICICI in 1984 and over three decades rose through the ranks to become MD and CEO. Under her leadership, ICICI Bank has expanded its branch network, improved credit quality, and shifted to a customer segmentation model. Kochhar aims to continue ICICI's growth above industry averages and make India a financial hub through economic growth, fiscal discipline, and regulatory reforms.
Kiran Mazumdar Shaw is an Indian businesswoman and the founder of Biocon, India's largest biotechnology company. She has over 40 years of experience in the biotechnology industry. Some key points:
- Founded Biocon in 1978 with just Rs. 10,000 in capital. Within a year, Biocon became the first Indian company to export enzymes to the US and Europe.
- Under her leadership, Biocon has become a billion dollar company and India's largest biotech firm. It develops biosimilar drugs and is a leading manufacturer of insulin.
- She is considered a pioneer in the Indian biotech sector and has helped establish several other biotech firms. Through her philanthropic foundation,
The document discusses various topics related to biotechnology and biomedicine from a global perspective. It provides an overview of biotechnology applications, major biotechnology companies worldwide with the US dominating, and achievements in biotechnology in countries like India, China, and the US. It also summarizes developments in areas like medical biotechnology, biomedical engineering, genomics, tissue engineering, and future directions of biomedicine involving concepts like lab-on-a-chip and nanosensors.
The document discusses the biotechnology industry in India. It notes that biotechnology draws from various disciplines like biology, biochemistry, and impacts areas like medicine, agriculture, and the environment. The Indian biotech industry has grown significantly in recent decades due to skilled labor and is a hub for global investment. The industry is projected to more than double in size over the next five years and reach $100 billion by 2025. It discusses the various segments of the Indian biotech industry and provides statistics on its size, growth rate, exports, and leading companies.
Biotechnology has been used for thousands of years to produce foods and materials through fermentation and selective breeding. Modern biotechnology began in the 1970s with genetic engineering techniques allowing manipulation of organisms at the molecular level. While biotechnology has benefits like producing lifesaving drugs and drought-resistant crops, it also raises ethical issues regarding genetic modification and patenting of life. Governments aim to balance biotechnology development with responsible social and environmental oversight to ensure its safe and equitable progress.
This document provides an overview of elements of biotechnology including definitions, types, areas of application, the Department of Biotechnology in India, biotechnology industries, and research and development in the field. It notes that biotechnology utilizes living organisms or their components to develop products and processes. The Department of Biotechnology was established in 1986 to support development and commercialization of biotechnology in India. Major areas of research include agriculture, health, and the environment.
1) Biocon was established in 1978 in Bangalore as a joint venture between an Irish company and Kiran Mazumdar-Shaw, initially focusing on producing enzymes.
2) In the 1980s, Biocon began focusing on solid state fermentation and built research capabilities. It also established subsidiaries like Syngene and Clinigene.
3) By the late 1990s and 2000s, Biocon transitioned to focus on biopharmaceuticals and launched several drugs. It also pursued growth through partnerships and acquisitions.
The document discusses the evolution and growth of India's biotechnology sector. Some key points:
- India has emerged as a dominant player in biotechnology, growing at 30-35% annually and becoming the 12th largest destination globally.
- The sector has grown from a small beginning 25 years ago when the Department of Biotechnology was established, to over 400 companies today employing hundreds of thousands.
- Indian biotech companies have developed drugs for diseases like cancer and diabetes and produce vaccines at significantly lower costs than international markets.
- The government has strongly supported the sector through funding, institutions, and a supportive regulatory environment. However, the regulatory process remains complex.
- India has strengths in human resources
The Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the US, and 25% of medicine in the UK. It is dominated by small and medium enterprises, though the largest 250 companies control 70% of the Indian market. India has gained prominence as the pharmacy of the world and biggest generic supplier due to its innovatively engineered generic drugs and active pharmaceutical ingredients. It accounts for around 30% of the $70-80 billion US generics market by volume and 10% by value.
The document provides an overview of the biotechnology industry in India. It notes that the Indian biotechnology sector is expected to reach $11.6 billion by 2017, making it the 12th largest in the world. The biotechnology industry in India is dominated by the biopharma segment, which accounts for over 60% of total revenue. Karnataka is a major hub for biotechnology in India, home to over 60% of Indian biotech companies and generating 50% of the country's total biotech revenue. The industry can be divided into segments including biopharma, bioservices, bioagriculture, bioindustrial, and bioinformatics. Major companies in the Indian biotechnology sector are discussed.
The document discusses the field of biotechnology, including its definition, types, applications, and status in India. It describes the six main types of biotechnology - red, white, yellow, grey, green, and blue biotechnology. The areas of application are discussed as health and medicine, food and agriculture, industrial and environmental applications, and plant biotechnology. Specializations within biotechnology like bioinformatics, genetic engineering, microbiology, and drug development are also summarized. The document concludes with details on the biotechnology sector and startups in India.
In the fast-evolving landscape of biotechnology, analyzing the Indian market holds significant importance. Our comprehensive biotech industry analysis delves deep into the dynamic realm of Indian biotechnology, uncovering key trends, market dynamics, and emerging opportunities.
With a focus on India's unique ecosystem, our analysis sheds light on the advancements in biotechnology, encompassing areas such as pharmaceuticals, genomics, healthcare, and life sciences. We explore the latest research and development initiatives, innovative startups, and disruptive technologies shaping the industry.
By examining the market landscape, regulatory environment, and competitive landscape, our analysis provides valuable insights for stakeholders seeking to understand the Indian biotech sector. From investors and entrepreneurs to policymakers and researchers, our research helps make informed decisions and identifies potential areas of growth and collaboration.
With an emphasis on industry trends, market projections, and emerging challenges, our analysis equips professionals with the knowledge needed to navigate the dynamic biotech landscape in India. Stay informed, make strategic moves, and unlock the immense potential offered by the Indian biotech industry with our in-depth analysis.
What Next After B.Sc., Biotechnology and Microbiology Avenues / CareersDr. Pavan Kundur
What Next After B.Sc., Biotechnology and Microbiology Avenues / Careers,
Here i tried to compile all the future opportunities in biotechnology and microbiology
Introduction to Biotechnology in India-History and Evolution. Brief Discussion about Current scenario and scope of Biotechnology in India and top companies.
Biotechnology is the use of living systems and organisms to develop or make useful products. It has applications in health care, agriculture, and industrial uses. Biotechnology parks provide financial and logistical support for new biotech entrepreneurs. They have been established in many Indian states. The biotechnology sector in India is growing and has potential to emerge as a global player due to research capabilities and cost-effectiveness. Biotech parks play key roles in health care, agriculture, industrial applications, and energy. Their focus areas include biofuels, crop improvement, health products, polymers, and more. India has strengths in human resources, research, and clinical capabilities for biotechnology but also faces weaknesses in commercialization, venture capital, IP protection
Biotechnology is the use of living systems and organisms to develop or make useful products. It has applications in health care, agriculture, and industrial uses. Biotechnology parks provide financial and logistical support for new biotech entrepreneurs. They have been established in many Indian states. The biotechnology sector in India is growing and has potential to emerge as a global player due to research capabilities and cost-effectiveness. Biotech parks play key roles in health care, agriculture, industrial applications, and energy. Their focus areas include biofuels, crop improvement, health products, polymers, and more. A SWOT analysis identifies strengths like human resources and opportunities like the large market, but also weaknesses like links between research and commercialization and threats
Biotechnology with agriculture is very useful in now a days and also in upcoming days. With the help of biotechnology we can produce better quality of crops and also increase the yield. The produces are also free from pests.
Biocon is India's largest biopharmaceutical company, established in 1978. It has grown from an enzyme manufacturing unit to a fully integrated biopharmaceutical enterprise. Biocon has shown strong financial performance over the years, with increasing profits and revenues. However, it has also faced some ethical criticisms over unapproved clinical trials that led to deaths and not following proper procedures. While Biocon's work in biotechnology is innovative, it must focus on conducting all activities ethically to ensure patient safety and trust in its products.
This document provides an overview of engineering chemistry, with a focus on biotechnology. It discusses key applications of biotechnology such as producing pharmaceuticals through gene cloning, developing genetically modified crops, and using microorganisms in food production and environmental remediation. The document also covers topics like fermentation processes, vitamin production, types of bioreactors, and the role of enzymes in industries.
The document discusses the scope for enhanced cooperation between Indian and German companies in the biotechnology sector. It provides an overview of the biotechnology industry in both countries, highlighting key areas like biopharmaceuticals, bioservices, bio-agri, and bioinformatics. The biotechnology market in India has grown significantly in the last decade and is projected to reach $100 billion by 2025, driven by factors like increasing government support and investments. The document identifies potential areas of collaboration between the two countries, including promoting academia-industry links, bilateral conferences, mentoring of Indian startups, and strengthening of clusters and incubators.
Similar to 45507055 final-project-report-kiran-mazumdar (20)
Introducing Milvus Lite: Easy-to-Install, Easy-to-Use vector database for you...Zilliz
Join us to introduce Milvus Lite, a vector database that can run on notebooks and laptops, share the same API with Milvus, and integrate with every popular GenAI framework. This webinar is perfect for developers seeking easy-to-use, well-integrated vector databases for their GenAI apps.
Generative AI Deep Dive: Advancing from Proof of Concept to ProductionAggregage
Join Maher Hanafi, VP of Engineering at Betterworks, in this new session where he'll share a practical framework to transform Gen AI prototypes into impactful products! He'll delve into the complexities of data collection and management, model selection and optimization, and ensuring security, scalability, and responsible use.
Unlock the Future of Search with MongoDB Atlas_ Vector Search Unleashed.pdfMalak Abu Hammad
Discover how MongoDB Atlas and vector search technology can revolutionize your application's search capabilities. This comprehensive presentation covers:
* What is Vector Search?
* Importance and benefits of vector search
* Practical use cases across various industries
* Step-by-step implementation guide
* Live demos with code snippets
* Enhancing LLM capabilities with vector search
* Best practices and optimization strategies
Perfect for developers, AI enthusiasts, and tech leaders. Learn how to leverage MongoDB Atlas to deliver highly relevant, context-aware search results, transforming your data retrieval process. Stay ahead in tech innovation and maximize the potential of your applications.
#MongoDB #VectorSearch #AI #SemanticSearch #TechInnovation #DataScience #LLM #MachineLearning #SearchTechnology
UiPath Test Automation using UiPath Test Suite series, part 5DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 5. In this session, we will cover CI/CD with devops.
Topics covered:
CI/CD with in UiPath
End-to-end overview of CI/CD pipeline with Azure devops
Speaker:
Lyndsey Byblow, Test Suite Sales Engineer @ UiPath, Inc.
Enchancing adoption of Open Source Libraries. A case study on Albumentations.AIVladimir Iglovikov, Ph.D.
Presented by Vladimir Iglovikov:
- https://www.linkedin.com/in/iglovikov/
- https://x.com/viglovikov
- https://www.instagram.com/ternaus/
This presentation delves into the journey of Albumentations.ai, a highly successful open-source library for data augmentation.
Created out of a necessity for superior performance in Kaggle competitions, Albumentations has grown to become a widely used tool among data scientists and machine learning practitioners.
This case study covers various aspects, including:
People: The contributors and community that have supported Albumentations.
Metrics: The success indicators such as downloads, daily active users, GitHub stars, and financial contributions.
Challenges: The hurdles in monetizing open-source projects and measuring user engagement.
Development Practices: Best practices for creating, maintaining, and scaling open-source libraries, including code hygiene, CI/CD, and fast iteration.
Community Building: Strategies for making adoption easy, iterating quickly, and fostering a vibrant, engaged community.
Marketing: Both online and offline marketing tactics, focusing on real, impactful interactions and collaborations.
Mental Health: Maintaining balance and not feeling pressured by user demands.
Key insights include the importance of automation, making the adoption process seamless, and leveraging offline interactions for marketing. The presentation also emphasizes the need for continuous small improvements and building a friendly, inclusive community that contributes to the project's growth.
Vladimir Iglovikov brings his extensive experience as a Kaggle Grandmaster, ex-Staff ML Engineer at Lyft, sharing valuable lessons and practical advice for anyone looking to enhance the adoption of their open-source projects.
Explore more about Albumentations and join the community at:
GitHub: https://github.com/albumentations-team/albumentations
Website: https://albumentations.ai/
LinkedIn: https://www.linkedin.com/company/100504475
Twitter: https://x.com/albumentations
Sudheer Mechineni, Head of Application Frameworks, Standard Chartered Bank
Discover how Standard Chartered Bank harnessed the power of Neo4j to transform complex data access challenges into a dynamic, scalable graph database solution. This keynote will cover their journey from initial adoption to deploying a fully automated, enterprise-grade causal cluster, highlighting key strategies for modelling organisational changes and ensuring robust disaster recovery. Learn how these innovations have not only enhanced Standard Chartered Bank’s data infrastructure but also positioned them as pioneers in the banking sector’s adoption of graph technology.
TrustArc Webinar - 2024 Global Privacy SurveyTrustArc
How does your privacy program stack up against your peers? What challenges are privacy teams tackling and prioritizing in 2024?
In the fifth annual Global Privacy Benchmarks Survey, we asked over 1,800 global privacy professionals and business executives to share their perspectives on the current state of privacy inside and outside of their organizations. This year’s report focused on emerging areas of importance for privacy and compliance professionals, including considerations and implications of Artificial Intelligence (AI) technologies, building brand trust, and different approaches for achieving higher privacy competence scores.
See how organizational priorities and strategic approaches to data security and privacy are evolving around the globe.
This webinar will review:
- The top 10 privacy insights from the fifth annual Global Privacy Benchmarks Survey
- The top challenges for privacy leaders, practitioners, and organizations in 2024
- Key themes to consider in developing and maintaining your privacy program
Building RAG with self-deployed Milvus vector database and Snowpark Container...Zilliz
This talk will give hands-on advice on building RAG applications with an open-source Milvus database deployed as a docker container. We will also introduce the integration of Milvus with Snowpark Container Services.
20 Comprehensive Checklist of Designing and Developing a WebsitePixlogix Infotech
Dive into the world of Website Designing and Developing with Pixlogix! Looking to create a stunning online presence? Look no further! Our comprehensive checklist covers everything you need to know to craft a website that stands out. From user-friendly design to seamless functionality, we've got you covered. Don't miss out on this invaluable resource! Check out our checklist now at Pixlogix and start your journey towards a captivating online presence today.
Removing Uninteresting Bytes in Software FuzzingAftab Hussain
Imagine a world where software fuzzing, the process of mutating bytes in test seeds to uncover hidden and erroneous program behaviors, becomes faster and more effective. A lot depends on the initial seeds, which can significantly dictate the trajectory of a fuzzing campaign, particularly in terms of how long it takes to uncover interesting behaviour in your code. We introduce DIAR, a technique designed to speedup fuzzing campaigns by pinpointing and eliminating those uninteresting bytes in the seeds. Picture this: instead of wasting valuable resources on meaningless mutations in large, bloated seeds, DIAR removes the unnecessary bytes, streamlining the entire process.
In this work, we equipped AFL, a popular fuzzer, with DIAR and examined two critical Linux libraries -- Libxml's xmllint, a tool for parsing xml documents, and Binutil's readelf, an essential debugging and security analysis command-line tool used to display detailed information about ELF (Executable and Linkable Format). Our preliminary results show that AFL+DIAR does not only discover new paths more quickly but also achieves higher coverage overall. This work thus showcases how starting with lean and optimized seeds can lead to faster, more comprehensive fuzzing campaigns -- and DIAR helps you find such seeds.
- These are slides of the talk given at IEEE International Conference on Software Testing Verification and Validation Workshop, ICSTW 2022.
Alt. GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using ...James Anderson
Effective Application Security in Software Delivery lifecycle using Deployment Firewall and DBOM
The modern software delivery process (or the CI/CD process) includes many tools, distributed teams, open-source code, and cloud platforms. Constant focus on speed to release software to market, along with the traditional slow and manual security checks has caused gaps in continuous security as an important piece in the software supply chain. Today organizations feel more susceptible to external and internal cyber threats due to the vast attack surface in their applications supply chain and the lack of end-to-end governance and risk management.
The software team must secure its software delivery process to avoid vulnerability and security breaches. This needs to be achieved with existing tool chains and without extensive rework of the delivery processes. This talk will present strategies and techniques for providing visibility into the true risk of the existing vulnerabilities, preventing the introduction of security issues in the software, resolving vulnerabilities in production environments quickly, and capturing the deployment bill of materials (DBOM).
Speakers:
Bob Boule
Robert Boule is a technology enthusiast with PASSION for technology and making things work along with a knack for helping others understand how things work. He comes with around 20 years of solution engineering experience in application security, software continuous delivery, and SaaS platforms. He is known for his dynamic presentations in CI/CD and application security integrated in software delivery lifecycle.
Gopinath Rebala
Gopinath Rebala is the CTO of OpsMx, where he has overall responsibility for the machine learning and data processing architectures for Secure Software Delivery. Gopi also has a strong connection with our customers, leading design and architecture for strategic implementations. Gopi is a frequent speaker and well-known leader in continuous delivery and integrating security into software delivery.
A tale of scale & speed: How the US Navy is enabling software delivery from l...sonjaschweigert1
Rapid and secure feature delivery is a goal across every application team and every branch of the DoD. The Navy’s DevSecOps platform, Party Barge, has achieved:
- Reduction in onboarding time from 5 weeks to 1 day
- Improved developer experience and productivity through actionable findings and reduction of false positives
- Maintenance of superior security standards and inherent policy enforcement with Authorization to Operate (ATO)
Development teams can ship efficiently and ensure applications are cyber ready for Navy Authorizing Officials (AOs). In this webinar, Sigma Defense and Anchore will give attendees a look behind the scenes and demo secure pipeline automation and security artifacts that speed up application ATO and time to production.
We will cover:
- How to remove silos in DevSecOps
- How to build efficient development pipeline roles and component templates
- How to deliver security artifacts that matter for ATO’s (SBOMs, vulnerability reports, and policy evidence)
- How to streamline operations with automated policy checks on container images
Climate Impact of Software Testing at Nordic Testing DaysKari Kakkonen
My slides at Nordic Testing Days 6.6.2024
Climate impact / sustainability of software testing discussed on the talk. ICT and testing must carry their part of global responsibility to help with the climat warming. We can minimize the carbon footprint but we can also have a carbon handprint, a positive impact on the climate. Quality characteristics can be added with sustainability, and then measured continuously. Test environments can be used less, and in smaller scale and on demand. Test techniques can be used in optimizing or minimizing number of tests. Test automation can be used to speed up testing.
2. AdArsh institute of
mAnAgement
mArgAo – goA
Indian Biotech Queen-Kiran Mazumdar
Shaw
Done by:
The Biocons
Khalandar Sha Khan
Prajot Morajkar
Swati Jampala
Saiesh Prabhu
Vinod Sawant
3. Contents of the Project:
1) Kiran Mazumdar Shaw
1) Introduction
2) Educational Qualifications & Personal life
2) Industry Review of Biotechnology
1) Introduction of Biotechnology.
2) Biotechnology Industry in India
3) Company Review of Biocon
1) History
2) Major Products of Biocon
3) Profitability Position
4) Strength of Employees
5) Success of Biocon
6) Controversy related to Biocon
7) Achievements of Biocon
8) Corporate Governance
4) Analysis of Kiran Mazumdar Shaw
4. 1) As an Entrepreneur
2) Personality Traits
3) As a Leader
4) Awards
5) Conclusion
1) KIRAN MAZUMDAR SHAW
Introduction:
Kiran Mazumdar Shaw is an Indian Businesswoman who was born on March 23, 1953 in
Bangalore. She founded the company Biocon in India in the year 1978. From what started as
an Indian subsidiary company of the Irish parent company Biocon, today Biocon is the
leading biotechnology company in India. She has been a huge factor in making the company
evolve from an industrial enzymes manufacturing company to a fully integrated bio-
pharmaceutical company. Biocon today is no longer a subsidiary company and it is a full
enterprise of its own of which Kiran Mazumdar Shaw is a Chairman and the Managing
Directori
. Biocon is also India’s first biotech company. She has established two subsidiaries
to Biocon named Syngene (a custom research organization) in 1994 and Clinigene (a clinical
research organization) in 2000 where she is the Chairman of both the companies.
She is a huge promoter of biotechnology sector in India and is a member of the Advisory
Council of the Indian government’s Department of Biotechnology where she has played a
great role in bringing the Indian government, industry and academia together for the growth
of this sector in India. She is highly respected in the corporate world because of her
tremendous work in biotechnology.
Kiran Mazumdar Shaw is responsible for steering Biocon on a trajectory of growth and
innovation over the years. Within a year of its inception, Biocon became the first Indian
5. company to manufacture and export enzymes to USA and Europe. In 1989, Biocon became
the first Indian biotech company to receive US funding for proprietary technologies. In 1990,
she upgraded Biocon’s in-house research program, based on a proprietary solid substrate
fermentation technology. The commercial success of this program led to a three-fold
expansion by 1996 and Biocon entered the biopharmaceuticals and statins segments. In 1997,
she undertook initiatives in human healthcare through a dedicated manufacturing facility.
Under her leadership, Biocon is building cutting-edge capabilities, global credibility and
global scales in its manufacturing and marketing activities. It has Asia’s largest insulin and
statin facilities as also the largest perfusion-based antibody production facilities. It was
included in ‘The best under a billion’ listing by Forbes in 2009. Her efforts in biotechnology
have drawn global recognition both for the industry in India and for Biocon and she has been
termed India’s Biotech Queen by ‘The Economist’ and India’s mother of invention by ‘The
New York Time
Educational Qualifications & Personal Life
Kiran Mazumdar Shaw was born in Bangalore. She did her schooling from Bishop Cotton
Girl’s High School in Bangalore. She wanted to join a medical school but took up biology
instead and completed her B.Sc. in Zoology with Honors from Bangalore University in 1973.
She did her post graduation in Malting and Brewing from Ballarat College, Melbourne
University in 1975. Her father was also a brewer and she worked as a Trainee Brewer in
Carlton and United Breweries, Melbourne and as a Trainee Malster at Barrett Brothers and
Burston, Australia but when she returned to India she found out that daughters were not
welcome in India’s breweries. In India, she was unable to find a job because of her gender,
hence she was planning to go abroad to have a career in brewing. She is married to a
Scotsman John Shaw, who is currently the Vice-Chairman of Biocon.iv
6. 2) Industry Review
Introduction of Biotechnology:
Biotechnology refers to the use of microorganisms such as bacteria or biological substances
such as enzymes, to perform industrial or manufacturing processes. Biotechnology is being
used to produce drugs and synthesize hormones.
Biotechnology is divided into three sub fields:-
1) Red Biotechnology
Red biotechnology deals with genetically changed microorganisms being used for
manufacturing products like insulin and vaccine for medical use. It is due to research
in red biotechnology that antibiotics for various infections have been developed and
vaccines to bolster the bodies’ resistance to various diseases were developed. It has
also been used in reproductive technologies like invitro fertilization, DNA profiling,
forensics and transplantation technologies.
2) White Biotechnology
White biotechnology deals with creating useful chemicals for the industrial sector
through organisms like moulds or yeast. This type of bio technology is also referred to
as grey biotechnology. White biotechnology has proven to be of immense benefit
environmentally in cleaning oil spills and in storing DNA samples of endangered
species for future research. It is also useful for removing excess nutrients in soil and
water and for detection of landmines.
3) Green Biotechnology
Green biotechnology also called agricultural biotechnology is to do with factors
pertaining to agriculture. Green biotechnology is concerned with the genetic
modification of plants and animals to produce environmentally friendly species.
7. The Biotechnology Industry
Before 1970, biotechnology was used mainly in the agricultural and food processing
industries. Today, their area of expertise extends much further. Biotech companies view their
work as an amalgamation of disciplines like genetics, biochemistry, embryology, molecular
biology and cell biology. This industry is about over 30 years old and is generating over $85
billion in revenues. There are 8,550 companies worldwide, of which 1420 are public
company.
According to Ernst & Young's 2007 Global Biotechnology Report, the biotech industry made
historic progress with strong product pipelines and product successes, record-breaking
financing totals, unprecedented deal activity and impressive financial results. The global
biotech revenues of the public listed companies in 2006 grew to $73.5 billion recording a 14
percent growth over that in 2005 ($64 billion). Further, according to the report, all the leading
regions in the world recorded a strong double digit growth, with the US and Europe recording
13 percent growth each and Canada registering 22 percent growth.
The biotech industry can be classified into five different segments: Biopharma, Agri-biotech,
Bioinformatics, Bio industrial and Bio services with each concentrating on a particular area.
• Biopharma deals with the production of vaccines, therapeutics and diagnostics, while
the end products of the biotech industry find two different kinds of buyers, the first
type include private hospitals, governments, patients and the second type include
industries like pharmaceutical.
• Agri-biotech deals with hybrid seeds and transgenic crops, biopesticides and
biofertilizers.
• Bio informatics deals with creation and maintenance of extensive electronic
databases on various biological systems.
• Bioservices market deals with clinical trial, contract research and manufacturing
activities.
• Bio Industrial industry deals with enzyme manufacturing and marketing companies
and these enzymes are used in detergent, textile, food, leather, paper and
pharmaceutical industry.
Role of the Biotechnology Industry:
• 200 plus vaccinations, products, therapies have been created by the biotechnology
industry to combat cancer, autoimmune syndromes, diabetes, HIV/AIDS etc.
• Biotechnology industry has developed several environment friendly products treating
elements which pollute the environment.
• Biotechnology is also used in industrial houses for the optimum usage of the various
forms of energy.
8. • Biotechnology industry also plays a significant role in taking forensic science ahead
by using methods relating to DNA fingerprinting.
• Biotechnology companies use biological systems, living organisms or their
derivatives to make products for specific use. The general opinion about top biotech
companies is that they spend billions of dollars in research and development, and do
little else. With such large inputs, such companies must create novel technologies and
products to stay solvent.
Bio Technology Industry in India
In India the Department of Biotechnology (DBT) was established in the year 1986 under the
ministry of Science and Technology This industry is one of the sunrise sectors in India. In
terms of number of biotechnology companies, India was ranked at number three position after
Korea and Japan in the entire South-Easter Asia and Globally India is in the list of top 12
biotech markets.
Out of these Bio-pharma is the largest on that contributes 65% of the total revenue from this
industry.
At present there are more than 350 biotech companies in India providing employment for
over 20,000 scientists. Most of the companies are located in the six major cities of Delhi,
Mumbai, Pune, Chennai, Bangalore, Hyderabad and Ahmadabad. To keep pace with the
competitive world, India has launched a comprehensive programme in biotechnology to make
use of the resources available. In India Biotechnology is been used in a wide range of
economic activity ranging from environment, animal husbandry, medicinal and aromatic
plants, bio fuels, aquaculture and products like silk and leather.
Bio technology industry in India is the fourth largest adopter of biotech crop in the world,
replacing Canada. India is gaining recognition in the field of clinical trial. A large number of
companies are providing research and development expertise to global pharmaceutical
companies. Many Indian Bio technology companies are also expanding overseas, for example
Biocon has acquired 70 per cent stake of the German pharma company AxiCorp by Biocon is
a case in testimony.
Growth in the Biotech Industry in India
With the growth in the customer base and more investments taking place in the biotech
sector, Biotech Industry is expected to grow to around Rs. 4, 40,000 crores by the year 2020.
The high demand for different biotech products has also opened up scopes for the foreign
companies to set up bases and reap great profits. Some of the positive facts about the growth
of the biotech sector in India are:
• The biotech sector has crossed $1 billion
• There has been a high growth of the Bio Agri sector in the country.
• With the introduction of new technologies, the sector has grown to Rs 598 crore from
Rs 330 crore
9. The government has also taken good steps to boost the biotech industry in the country, more
and more innovations have been made in this field to combine rich knowledge with skilled
manpower. A number of research laboratories have been set up in this regard to facilitate the
growth of the sector. This has led to the innovation of various drugs for the production of
insulin, blood clotting, human growth and so on. Life saving vaccines and enzymes have also
been manufactured.
Challenges faced by the Indian biotech industry
Despite having established drug development firms and renowned research expertise, the
Indian biotechnology industry is facing a cash crunch. Inherent challenges facing the biotech
outsourcing business are the lack of appropriate infrastructure, issues arising under the
Intellectual Property Rights (“IPR”) laws, product liabilities, ensuring exclusivity and the
need for increased industry-academia partnerships. Other issues that require attention include
but are not limited to: Exchange Control regulations; labour laws; contract terms and
conditions; mechanisms for dispute resolution and the tax issues relating to withholding tax,
transfer pricing and tax holidays/exemptions, etc.
Key drivers of the Indian biotech industry
- A number of biogenerics are slated to go off patent in the coming years, opening
opportunities for Indian firms. Frost & Sullivan reckons that the US and Europe alone offer
potential to generate sales of $16.4 billion by 2011. Besides, the Indian market itself is
quite large, thanks to changing economic demographics .
- Our competitive edge comes from strong bio- manufacturing skills coupled with low-cost
base, generating high capital efficiency.
- It is now possible to establish that indigenously made biosimilar drugs are comparable to
the original products through pharmacokinetic, pharmacodynamic, and clinical studies. A
plus factor from India's perspective.
- Imminent introduction in the U.S. and Europe of a regulatory framework for approving
generic versions of biologicals considerably improves our sales and marketing prospects
Suggested measures for growth of biotech industry in India
- To allow 100% FDI by automatic route in the biotech sector
- Biotechnology should also get the “priority sector” tag for lending funds by banks for long
gestation projects
- To introduce fiscal measures that support incremental R&D investment
- To desist from any price control measures
- To strengthen human resources with an objective of meeting the industry demand in terms
of specialized skills.
10. - To improve the Regulatory and IP infrastructure.
Future Growth of the Indian biotech industry
The Indian Biotech sector is on a growth trajectory with the potential to deliver $5 billion
revenues by 2010 and $20 billion by 2020. If the National Biotech Strategy is successfully
implemented, this ambition will be easily achieved. We need to focus on creating a strong
educational foundation in terms of higher and specialized education and on forging strong
links between Industry and Academia.
ii
International Biotech
Companies
Top Indian Biotech
Companies
International Biotech
Companies in India
Genentech Inc. Biocon Monsanto
Amgen Inc. Shantha Biotechnics Pfizer
Gilead Sciences Inc. Bharat Biotech Astra Zeneca
Genzyme Corporation Wockhardt Unilever
Serono S.A Dr. Reddy's Laboratories Dupont
Biogen Idec Inc. Serum Institute of India Bayer
MedImmune Inc. Zydus Cadila Eli Lilly
Chiron Corporation Aventis Pharma Hoechst Roussel Vet
Amylin Pharmaceuticals
Inc. Reliance Life Sciences Millipore
Invitrogen Corporation Panacea Biotec Novozymes
11. 3) Company Review
History
While planning for a brewing career abroad, Kiran Mazumdar had a meeting with Les
Auchincloss who had started a biotechnology company called Biocon in Ireland. He asked
her to be his business partner and start Biocon in India. As she wasn’t having any
entrepreneurial background, she refused the offer. However, Les Auchincloss persuaded her
to give it a try with a buy-back clause if the business failed, she finally accepted and spent six
months in Ireland and underwent training for the job.
She started Biocon in 1978 in Bangalore with Rs. 10,000 as the initial capital as she faced
credibility challenges because of her youth, gender and her untested business model. Funding
was a big problem for her as no bank wanted to lend finance to her. After failing to find any
financial institution to back her, she also found it difficult to recruit people for her start-up.
She began operations out of the garage of a rented house with two employees. She faced
several hurdles. Uninterrupted power, superior quality water, sterile labs, imported research
equipment, and advanced scientific skills were not easily available in India during the time.
The company was operating in an environment with sub-optimal infrastructure and
personally she was a 25-year-old first-generation woman entrepreneur without business
experience. There was the risk of the business of biotechnology itself, an unknown business
in 1978.iii
Biocon’s first product to go to market was peptinpapain, an enzyme found in papaya which is
used to prevent beer from turning hazy. Until 1983, the company blended enzymes and
supplied them to brewing, textiles, biofuels, animal feed and other such industries across the
world. In the mid-1980s with a loan of US $250,000 from ICICI Bank, Biocon was able to
build a solid-state fermentation plant which helped in the growth of its R&D. iv
In 1989, the Irish Biocon was acquired by Unilever. In the 1990s, Kiran Mazumdar-Shaw
decided to focus on biopharmaceuticals rather than enzymes. Unilever, which was a major
shareholder, did not want to be in the biopharmaceuticals business. John Shaw, the Scotsman
whom Kiran Mazumdar-Shaw had married in 1998, used his savings to reclaim the entire
Biocon stake from Unilever.v
12. Biocon ventured into the lucrative biopharmaceutical segment. They sensed a great
opportunity when branded drugs went off patent. They began to develop lovastatin, a
cholesterol-lowering drug whose patent expired in 2001. Biocon eventually began making
other forms of statins. The company’s revenue went up from Rs. 70 crore in 1998, to Rs. 500
crore in 2004 when it went public.
In 2007, Biocon made a strategic decision to divest its historic enzymes business to
Novozymes A/S of Denmark. Today, Biocon has evolved from an enzyme company to a fully
integrated biopharmaceutical company.vi vii
It is the first company globally to manufacture human insulin, Insugen®
using a Pichia
expression system. In 2006, Biocon launched BIOMAb EGFR®
the first indigenously
developed humanized monoclonal antibody for head-and-neck cancer.
13. Major Products of Biocon:
Biocon’s products are based in four areas such as Diabetology, Cardiology, Nephrology and
Oncology. Biocon’s cardiology, nephrology, diabetology and oncology products including
BESTOR®
, BASALOGTM, BioMAb EGFR®
, STATIX®
, NUFIL safeTM
, INSUGEN®
,
TACROGRAFTM
, ERYPRO safeTM
, and MYOKINASETM
are considerably less expensive
than other leading brands. Two of its novel programs on the verge of proof-of-concept stage
are IN-105, which is the only oral insulin in the world to be in long duration clinical trials,
and the T1h, a novel humanized monoclonal antibody (MAb), the only first-in-class novel
MAb being tested in India for rheumatoid arthritis and psoriasis.viii
Biocon has a wide range of products under different categories as listed below:-
Biopharmaceuticals:
Active Pharmaceutical Ingredients (APIs)
• Anti-Diabetic Agents
• Anti-Inflammatory Agents
• Anti-Oxidants
• Cardiovascular Agents
• Anti-Obesity Agents
• Digestive-Aid Enzymes
• Anti-Hypertensive Agents
• Haemostatic Agents
• Hepatoprotective Agents
• Immunosuppressants
• Gastro-Intestinal Agents
• Nutraceuticals
Biological:
• Insulin
• Streptokinase
• EPO
16. PROFITABILITY:-
Biocon Ltd’s profitability improved in the quarter ended September, as it benefited from
higher sales and licensing income. During the quarter, sales of biopharmaceuticals rose by
19% to Rs. 601 crore, with product sales rising by 16%, while licensing income doubled to
Rs. 23 crore. It has an alliance with US-based Mylan Inc. and receives license income based
on the progress of work. The first biosimilar product under this alliance has entered the pre-
clinical trials phase, said the company.
Biocon has also announced a $350 million (around Rs. 1,500 crore) licensing arrangement
with Pfizer Inc. pertaining to its insulin products. Its share price has risen nearly 10% since
the announcement was made, explaining why the good results did not move the stock.
Biocon’s revenue rose by 17% and its material costs rose by only 15%. But a decline in other
expenses and slower growth in material costs enabled it to improve its operating profit
margin by 170 basis points. Its profit-before-tax rose by 26% but higher taxes lowered the net
profit growth to 20%.
The company’s biopharmaceuticals business is doing well, with branded formulations’ sales
up by 32% year-on-year in the first half of the year. It has started two new divisions of
immunotherapy and comprehensive care. Its German subsidiary AxiCorp GmbH won some
key tenders for supplying generic drugs, and its sales rose by 30% to Rs. 523 crore in the first
half. Biocon’s biopharmaceutical division is expected to do well in the second half as well.
On the research front, a key development is the company deciding to launch its oral insulin
simultaneously worldwide, which will involve carrying out US clinical trials. Earlier, the
company was contemplating an India launch, followed by a roll-out in other markets. The
company believes the benefits of following this approach will be substantially higher. Its
research services business saw slow growth of 7% in the second quarter, which appears to
partly be a result of an effort to focus only on value-added work.
In the near term, the inflows from the Pfizer transaction will hold investor interest. Around
$200 million will be in the form of an upfront payment, though it will reflect in Biocon’s
profit and loss statement in stages. It will use this money to fund its capital investments and
regulatory filing fees, which would have otherwise put a strain on its finances. This will
ensure that Biocon can fund its growth without resorting to more borrowings. As of
September, its debt levels have fallen by 17%. Biocon’s per share earnings, based on
consensus estimates, are expected to rise by 13% in fiscal 2011 and by 17% in fiscal 2012. Its
share trades at around 26 times its fiscal estimated 2011 earnings. That appears justified,
given the boost to its business from the Pfizer transaction, and its earnings so far having risen
much faster.
17. Biocon Continues to Deliver Strong Performance
Biocon Limited announces earnings for the half year ended September 30, 2010. Revenues at
Rs 1,360 crores; EBITDA at Rs 293 crores; PAT at Rs 166 crores
Commenting on recent developments, Chairman and Managing Director Kiran Mazumdar-
Shaw said, “This is an exciting time for Biocon. Our strategy of building and unlocking high
value innovation in Biotechnology has seen us enter into a new phase of growth. The recently
announced global commercialization alliance with Pfizer is a validation of this approach. All
our core businesses have delivered robust performance for the first half of this fiscal and are
expected to sustain this level of growth for the rest of the year.”
For Half-Year ended September 30, 2010
• Total Income at Rs 1,360 crores. Up 24% YoY.
• EBITDA at Rs 293 crores. YoY growth was 24%.
• PAT at Rs 166 crores. YoY growth was 26%.
• Operating Margin at 22%.
• Earnings Per Share at Rs 8.5.
• Headcount at 5,100+ employees.
For three months ended September 30, 2010
• Total Income at Rs 688 crores. Up 16% YoY.
• EBITDA at Rs 153 crores. YoY growth was 21%.
• PAT at Rs 89 crores. YoY growth was 20%.
• Operating Margin at 22%.
• Earnings Per Share at Rs 4.5
The global bio-similars market is expected to be worth $19 billion by 2014. Biocon
outsourced Research and Development globally for the year 2009 which was worth $30
billion. Between 2005-10, more than 2.200 high value R&D licensing and other deals were
done within the biopharmaceutical and pharmaceutical space. Net income increased 44% to
Rs. 24,048 million crossing the $ half billion mark. Profits grew 215% to Rs. 2933 million.
Pharmaceutical Business exceeded Rs. 20,871 million in revenue and the Net R&D
expenditure increased to Rs. 917 million, up 42% over 2008 and up 282% over 2005. It
acquired The Bulk Pharmaceutical Plant of IDL Specialty Chemicals Limited in this fiscal
year. Research services business crossed Rs. 2807 million.vii
18. STRENGTH OF EMPLOYEES:-
Today, Biocon has world-class research outsourcing capabilities, US FDA-compliant bio-
manufacturing facilities and a self-financed R&D pipeline. As we can see in the table below, Biocon
has been providing employment to the youth and employs about 4478 employees including the
subsidiaries.The hire Biologists, chemists, medical practitioners, pharmacologists, engineers,
finance/legal/marketing analysts, HR generalists and general administrators. Around 6% of its
employees have PhD degrees, 45% have a post graduate master’s degree, and 33% are graduates.
Biocon also collaborates with educational institutes to make courses more industry oriented. It is
regarded as the 7th largest employer among the top 100 global biotechnology companies.
Success of Biocon:
The Biocon India Group story began in 1978 when Leslie Auchincloss, owner of the small
Irish multinational company Biocon Biochemicals and Kiran Mazumdar founded Biocon
India - owned 70 per cent by Kiran and 30 per cent by the Irish company. The business was
established In Bangalore and Ms Mazumdar was appointed Chairman & Managing Director.
In 1983 the company acquired 20 acres of land close to Bangalore city and moved its
operation where it is presently located.
In 1989 a new phase in the development of Biocon India opened when Biocon Ireland was
acquired by the Anglo Dutch giant - Unilever. Unilever thereby acquired the 30 per cent
19. holding in Biocon India owned by Biocon Ireland. As a result of this, Biocon India became
an associate of the multinational giant.
In 1997 when Unilever put its Specialty Chemicals Division up for sale. it was purchased by
lCI (Imperial Chemical Industries) in a global deal valued at $9 million. As a result, the
shareholding In the Biocon India Group was transferred from Unilever to ICI ownership. This
gave Ms Shaw the opportunity to negotiate with ICI as the articles of the various companies
in the Biocon Group gave pre-emptive rights to existing shareholders.
Eventually her husband John Shaw purchased the entire shareholding of ICI in the various
Biocon India Group companies and joined the management team of the group. As a result of
this transaction, the Biocon India Group Companies were owned and controlled by Ms Shaw
and her husband with key employees participating via various stock option schemes.
An associate company or Biocon, Syngene International was established in 1994 to carry out
drug-based contract research as well as informatics- based software development for the
pharmaceutical industry. Syngene International designs and manages research projects for
companies with interests in pharmaceuticals and biotechnology. Syngene's strengths lie in the
areas of molecular biology, synthetic chemistry and informatics.
In August 2000, Clinigene International was established to conduct longitudinal clinical
studies in select disease segments.
The diversity and density of Indian patient populations was perceived to be a unique niche for
Clinigene to pursue a new approach in specialised clinical studies with a view to create new
medical wisdom.
The objective was to create clinical data bases that can be used to identify new biomarkers as
well as other genotypic and phenotypic disease indicators. For this purpose Biocon has tied
up with Strand Genomics. Strand Genomics studies the trends and patterns in the data to
identify new biomarkers. Biocon has also entered into a joint venture with Shantha Biotech to
produce and market Human Insulin.
Controversies:
In the year 2008, villagers of the Hebbagodi region claimed that the company had polluted air
and ground water, where the company's factory is located. They held a protest march and the
angry villagers protested in front of the Biocon factory in Hebbagodi. K M Muniratnam, a
handicapped fisherman accused the company over the huge losses he had sustained over the
last 3 years, as the fish he reared in the lakes were dying due to chemical effluents from the
factory. He had taken the licence to fish in two lakes in the Hebbagodi region, but there had
been at least six occasions when the fish had died. The company had told K M Muniratnam
that they'll pay compensation, but he didn’t get anything. Hebbagodi residents complained
about the contamination before, but no one took notice is what they claimed.
A government analysis in 2007 showed industrial discharge was harming water quality.
People were suffering from skin diseases, headaches, kidney problems. A government
20. assurance about starting a river water supply to these areas got the protestors to put off their
strike.
But the Biocon company officials replied that they were being unfairly blamed. The COO of
Biocon Arun Chandavarkar claimed that Biocon in no way was connected to quality of water.
Bad smell had been a problem earlier but over the last two years, they claimed to have taken
many steps to reduce the odour.
Biocon’s Methylcobalamin Row
In 2006, there was a lot of controversy surrounding Biocon Ltd, one of the leading biotech
companies in India, for allegedly violating certain norms of manufacturing Methylcobalamin.
The controversy was that Biocon had requested the Union Government for a license to import
the base material and manufacture Methylcobalamin (MeB12) in India.
The company had also obtained license from the Karnataka government to manufacture the
drug in seven stages. On March 17, 2003, the Karnataka government had given license (No.
46 A-MF 668) to manufacture the drug in seven stages. On January 17, 2006, the office of the
drug controller of Karnataka on a routine inspection found that Biocon was not
manufacturing the product in its Bangalore facility and that it was importing the drug from
China. The state government then cancelled the license due to this.
The Karnataka health minister during that year, R Ashok pointed out that the company had
not manufactured the drug as per the seven stages and that government rule clearly states that
if there are any changes in the manufacturing of the drug, which was not according to the
license, then the company had to obtain permission from the government. Else it violates the
Rule 18 (g) under Drugs and Cosmetics Act.
Following the state government's notice to Biocon, the company admitted that they were
importing the drug without the government's permission. The State Drug Controller wrote a
letter to the Chief Drug Controller in Delhi on March 28, 2006 on this issue to take action
against the company.
On February 10, 2006, Biocon got the license from the Central government to import
Methylcobalamin. Kiran Mazumdar-Shaw, chairman and managing director, Biocon Ltd
informed, "Methylcobalamin is a form of Vitamin B12 and an internet search will indicate
that it is available internationally as a dietary supplement or nutritional supplement and is not
regulated as a drug in many countries. The other common forms of Vitamin B12 are
cyanocobalamin and hydroxocobalamin. However, in India, it has been regulated as a drug
since 2002."
Biocon initially intended to manufacture the product starting from cyanocobalamin using a
multi-step process for which it obtained a manufacturing license from the state drug
controller's office. But competition from cheaper imports made this unviable. Hence, Biocon
revised its manufacturing process to begin from an advanced intermediate with fewer
manufacturing steps without compromising the quality of the final product. However, there
was a regulatory oversight in not updating the manufacturing license to reflect the new
manufacturing process. During a routine inspection, the state drug controller's office noticed
21. this lapse and issued a show cause notice to Biocon. Biocon admitted the lapse and hence the
manufacturing license for the product was cancelled.
Biocon immediately stopped manufacturing the product and also stopped importing the
advanced intermediate. Biocon made a fresh application to the Central and state drug
controller's office and has obtained a fresh license from both. This is how the issue was then
resolved.
22. Awards and Achievements
Biocon has the following awards and achievements to its credit
2010:
Bio-Excellence Award for Outstanding Achievement in the Healthcare Sector at Bangalore
Bio
2009:
- Among Top 20 Indian companies in Forbes ‘Best Under A Billion’ list
- Bio-Excellence Award for Outstanding Achievement in the Healthcare Sector at Bangalore
Bio
- Bio-Excellence Award for outstanding achievement in the Biotech Service Sector at
Bangalore Bio for Syngene IDMA ‘Best Patent of the year’ award
- BIOMAb EGFR®
voted ‘Bio-Spectrum Asia-Pacific Product of the year’, 2008
- BioSingapore Asia Pacific Biotechnology Award for Best Listed Company
2008:
- Ranked among the top 20 global biotechnology companies (Source: Med Ad News, June
2008)
- 7th largest biotech employer in the world (Source: Med Ad News, June 2008)
2007:
‘BioServices Company of the Year’ for Syngene, BIOMAb EGFR®
wins ‘Product of the
Year’, BioSpectrum Awards
2006:
Best IT User Award in the Pharmaceutical Sector, NASSCOM
2004:
- India's first and No. 1 biotech company with a global ranking of 16 (Source: Biospectrum,
July 2004)
- India's top 5 Life Sciences companies (at close of trade as on July 30, 2004)
- Best Reinvention of HR Function Award, Indira Group, Mumbai
- Best Employer of India Award, Hewitt
2003:
- Bio-Business Award for bio-entrepreneurship, Rabo India
- Express Pharma Pulse Award for excellence in the pharmaceutical industry
2001:
- Biotech Product, Process Development and Commercialisation Award, Department of
Biotechnology, Ministry of Science and Technology, Government of India
2000:
- Technology Pioneer Recognition, World Economic Forum 1985:
23. - Export Performance Award, Karnataka State Financial Corporation (KSFC)
- National Award for Best Small Industry, Government of India
Firsts
Set up in 1978, Biocon is India's first biotech company
• First Indian biotech company to receive US funding for proprietary technologies
(1989)
• Sets up India's first clinical research organization, Clinigene (2000)
• First Indian company to be approved by US FDA for the manufacture of lovastatin, a
cholesterol-lowering molecule (2001)
• First company worldwide to develop human insulin on a Pichia expression system
(2003)
• Biocon enters the stock market with its IPO and becomes only the second Indian
company to cross the $1-billion mark on the day of listing (2004)
• Launches India’s first cancer drug, BIOMAb EGFR®
(2006)
• First Indian company to manufacture and export enzymes to USA and Europe
• India’s largest producer and exporter of enzymes
• Releases country’s first 24-hour diabetes drug, Glargine (2009)
• First biotech company to receive ISO 9001 certification in India
• Syngene is country’s first custom research company in drug discoveryiv
24. CORPORATE GOVERNANCE
Biocon Foundation provides essential primary healthcare services to individuals and families
in target communities by means acceptable to them through their full participation and at
costs that they can afford. They have established Arogya Raksha Yojana (ARY) Clinics.
Delivering on its commitment to affordable healthcare, Biocon Foundation has been setting
up ARY Clinics in areas where large numbers of people are enrolled with the ARY health
micro insurance program. These Clinics have been set up to make primary healthcare
facilities more accessible and more affordable for surrounding communities. Supporting the
ARY micro insurance program, the Clinics will guide member patients to network hospitals
and help them avail of the benefits due to them.
Each Clinic is equipped with:
• a full-time doctor
• an ARY pharmacy stocking subsidized generic drugs
• a Laboratory offering basic diagnostic tests, at discounted rates
• a Mobile Medical Service to enable the clinic doctor and staff to travel to and provide
consultation at remote villages.
The Foundation currently runs seven clinics in both urban and rural settings. In Bangalore
their clinics are located at Austin Town, Huskur, Hennagara and K.R.Puram. The rest of the
clinics are in Mandya, Chickballapur and Bagalkote districts of Karnataka.
In 2008-09, the Arogya Raksha Yojana through its clinics had treated around 22,000 patients
and had assisted many with minor and major surgeries through the ARY health insurance
program. The ARY Clinic in Kaladgi, Bagalkote was an anchor point during the
Foundation’s flood relief effort in the aftermath of the devastating floods that hit North
Karnataka in October 09
Health Camps
General and specialized health camps are conducted in remote areas where good medical
facilities are not available. These camps provide cardiac, neurological, ophthalmic,
orthopedic, gynecological and general health checks. Three to four camps are held every
month in collaboration with Narayana Hrudayalaya and other network hospitals. Every camp
is attended by an average of 300 people.
In Oct 2009, the team from Biocon Foundation’s Health Program held numerous health
camps in the various flood hit villages in Bagalkote district of North Karnataka. The teams
also collaborated with the Government doctors and Public Health Center’s to ensure
maximum reach and effectiveness.. Through these health camps our doctors were able to
reach and help more than 5,000 people.
25. There has been tremendous progress in the treatment strategies for various diseases, which
were once considered inoperable. Unfortunately, most Indians cannot afford the cost of high
technology healthcare. For example, India requires a 2.5 million heart surgeries a year, but
has the capacity to do only about 80,000-90,000. India also has a very high incidence of head
and neck cancer, which can be cured if diagnosed early and proper treatment is given.
EDUCATION:-
In the area of child education, Biocon Foundation has collaborated with Pratima Rao, a
prominent educationist and Macmillan India, a leading educational publisher to inculcate a
love for math and self reliance in learning through innovative mathematics text books -
‘Chinnara Ganita’.
The project covered 11,000 children in Grade 1 & 2 in its first year and 15,000 children from
Grade 1 to 4 in the second year in rural districts of Karnataka.
Because of Biocon Foundation’s effort to increase access and exposure to learning
opportunities from children, the Aata Pata Wadi project was launched in 2009 with its first
Aata Pata Wadi (after school resource center) in Thithimati in Kodagu district of Karnataka.
The aim of these centers is to provide an open and fun learning environment for children,
many of who come from marginalized communities thus enabling them to nurture their
interests, learn new skills and awaken their spirit of enquiry.
Objectives:
• To provide access to computer aided leaning
• To emphasize experiential learning and extracurricular activities
• To boost language skills
• To provide life skills education
To encourage talent and support academics, Biocon Foundation has initiated a grant for
talented and deserving students of the Guha Centre for Genetic Engineering and
Biotechnology, University of Kolkata.
Kiran Mazumdar Shaw’s view about corporate social responsibility:- “I sincerely believe
that it is important to give back to society - the very society that has allowed us to attain the
heights we have. At Biocon, our efforts extend beyond the realm of biotechnology through
our community-support initiatives and corporate citizenship programmes. We recognise our
responsibility to India - her health, education and environment. Our particular focus is on
child welfare as we realise the importance of investing in children, to positively impact their
future. Biocon Foundation has been established with the aim of identifying and implementing
projects that will impact the social and economic scenario in the country. The main focus
areas of the Biocon Foundation are providing quality healthcare and health education for the
betterment of Indian society.”
26. 4) Analysis of Kiran Mazumdar
Shaw
As an Entrepreneur
Kiran Mazumdar Shaw, the chairperson of Biocon started her own business with just
Rs.10,000 in hand and a degree in Brewery, and went on to become the richest woman
entrepreneur in India though she actually became an entrepreneur by accident. Mrs. Shaw
wanted to start her Brewing industry and in spite of her degree she established Biocon in
1978 which lead to the foundation of India’s Biotech industry. But still she had to overcome
difficulty as banks refused to provide her loans due to the lack of assets and as she was a
woman entrepreneur which was a rare phenomenon. Above all, Biotechnology industry was a
new field at that point of time.
She has become the Poster Girl for Indian women entrepreneurs, and also a source of
inspiration to many others, though she had a number of failures, she still became a successful
leader. In India, Kiran Mazumdar Shaw is a motivator of all aspiring women entrepreneurs.
Personality Traits
According to us, a combination of several factors such as Determination, Confidence and
Motivation led her to build up a valuable organisation. Let us look at these traits in detail and
let us see how they have been factors for the success of Biocon.
Determination:
Initially when Kiran Mazumdar Shaw approached financial institutions, they refused it as:
Company had no assets.
Woman entrepreneur was a new word.
Biotechnology was a new concept to Indians.
In that stage also her determination to build up Biocon didn’t turn down. As a leader she used
to set possible goals like production of enzymes and antibodies from fermentation and
research process.
Confidence:
Her confidence level is clearly seen through her activities as she started her business in
relatively new and innovative field, even when banks refused loans to Kiran, she still went
against all odds as a belief that women can be entrepreneurs. The confidence of Kiran is
commendable when comparing that with the challenges that she faced. These challenges have
27. evolved with the growth of Biocon. Initial challenge that she faced was her young age, her
gender and the nature of unfamiliar business. There was no inflow of fund as banks refused to
give loans. Once she overcame all these, she had to face technological challenges to build a
Biotech business in a country like India which was not so good in infrastructure at that point
of time. The high-tech biotech industry was dependent on high quality, power, high
technological lab, equipments etc.
Now the challenges have moved on to maintain quality, about growth, managing a large
company and managing investor expectations like other CEO’s.
Motivation:
In Biocon, employee feedbacks are being regularly asked so as to motivate them and it will
further help them to excel in their field. In Biocon, performance checks are done annually and
implemented at the end of the financial year. It helps to measure employee performance and
also helps to reduce grievances. They also conduct Behavioural training, leadership
programs, and also provide with compensation packages. Due to all these HR policies, the
rate of attrition is less than 1% in Biocon. She has set up a mission for her to build pride into
her workplace and also into her country.
Work place principles which helped her to keep employees motivated are Excellence,
Integrity, Accountability, Organizational Pride, Fairness,Learning, Informality in work place,
Elegant and refined working environment.
Socially Responsible:
Along with the growth of Biocon she also involved her support in various community
programs and corporate citizenship initiatives with a focus in the areas of healthcare,
education, and environment. The Biocon Foundation in 2004, setup “Arogya Raksha Yojana”
which is a unique health initiative for rural India.
In her effort to protect the uniqueness of her hometown Bangalore, she has been involved in
various city improvement programs like the Bangalore Agenda Task Force (BATF).
Risk Taker:
Kiran Mazumdar Shaw is a risk taker, and it can be seen from the beginning of Biocon itself.
She has also proved it when she had done her Post-Graduate in brewery which had never
been touched by a woman in India. Further when she failed to continue her career in
Brewery, she was directed towards Biotechnology industry which was a new business to
Indians. But due to her confidence and determination she was able to be India’s richest
woman.
Other risks which she had taken in her organization were:
Beacon’s R&D programme was rapidly advanced
Took the risk to produce Oral Insulin an Anti - CD6 Monoclonal antibody.
28. These two are the leading discoveries in the field of research programs.
29. Innovative:
Kiran is an innovator in all sense, in creating a successful company, developing innovative
ideas, new products, etc. Also she has a clear vision and prefixed objective for her
organisation and to achieve those objectives, she encouraged her employees to think
innovative and keep on researching.
Some of the products of Biocon are:
INSUGEN R: It is useful when Oral agents fail to control blood glucose levels or
when therapy with Insulin.
BIOMAB-EGFR: This is used in head and neck cancer.
RAPACAN: This is used for the prevention of rejection and rescue therapy for
rejection in renal transplantation.
As a Leader
We say that Kiran Mazumdar Shaw is a transformational leader as she has similar personality
traits like that of other transformational leaders such as Richard Branson of Virgin group,
A.G. Lafley CEO of Proctor & Gamble. Kiran Shaw had a vision of her own and she never
followed the footsteps of others or never bothered about what others think or say about her.
She also possesses the ability to bring the changes or transform her organisation, and she also
has influential power to motivate and encourage her employees to think innovative and
research.
Eg. As the book Introduction to Organisational Behaviour by Robins, Judge, Sanghi;
describes A. G. Lafley as a transformational leader as he has brought flexibility and creativity
to a slow growing company and also the innovations which helped them to achieve the no. 1st
position from the 5th
position in United States for their brand and doubled the sales
worldwide. Whereas Mrs. Shaw started her business with the initial capital of Rs 10,000 and
at present the company is worth Rs. 1.79 crore. From this we can observe that she was
determined about her company’s success and also has taken number of risks and continued
innovating new products. As a result Biocon has become the number 1 biotech company in
India. ix
Kiran Mazumdar Shaw has transformed Biocon from an enzyme company to a fully
integrated biopharmaceutical company therefore on this basis we say that Mrs. Shaw is a
transformational leader.
30. Achievements of Kiran Mazumdar Shaw
Kiran Mazumdar Shaw is an entrepreneur who has the potential to take risk and she succeeded in
turning Biocon as India’s largest biotechnological firm. She has won many awards and honours. Some
of the major awards and prizes are:
She is the list of 100 most powerful women (by Forbes, 2010)
Nikkei Asia Prizes- Regional Growth by Nikkei Inc. (2009)
Express pharmaceutical leadership summit award for dynamic entrepreneur (2009)
Businesswomen of the year by Economic Times (2009)
Honorary Doctorate from university of Abertay Dundee UK.(2007)
Wharton Infosys Business transformation Award (2006)
Padma Bhushan (2005)
Honorary Doctorate from Manipal Academy of Higher education –MAHE (2005)
Life time Achievement Award from Indian chamber of Commerce (2005)
Honorary Doctorate of Science from Ballard University (2004)
The Economic Times Business Women of the year (2004)
Whirlpool GR8 women award for science and technology (2004)
Australian Alumni High Achiever Award from the IDP Australian Alumni
Association (2003)
Ernst & Young Entrepreneur of the Year Award in Healthcare & Life Sciences
Category (2002)
Woman of the Year from the International Women's Association, Chennai (1998–
1999)
Padma Shri (1989)
Outstanding Young Person Award by Jaycees (1987)
Rotary award for the Best Model Employer (1983)
Outstanding Contribution Award (AWAKE) (1983)
Gold for Best Woman Entrepreneur, Institute of Marketing Management (1982)
31. Conclusion:
We would like to conclude our project by mentioning the words of Kiran Mazumdar Shaw
herself. This is what she has to say:
“Life is about the very difficult journey. But it’s those difficulties that make it very
interesting, very exciting. If you had smooth sailing all the way I think life will be
very boring. But it’s those challenges that overcoming those challenges that gives you
a sense of confidence to move on. So my advice to young people is Don’t Give Up.
Life and entrepreneurship is about failures, but learn from these failures. Because
failing is big experience, big learning. It makes you stronger, it makes you very
confident when you actually overcome that failure. You know, Yes it’s demoralising
and demotivating if you keep failing and if you keep making same mistakes over and
over again then there is something radically wrong, but by failing and picking
yourself up and then succeeding believe me that failure is a big big deal in itself. I
have done it and I belong to it all the way.” but its most failure that they made very
strong because every time I picked myself up and then succeeded. It’s those failures
that I remember which they really made me very strong.”x